Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors
Summary
This study has three parts. Part 1 is a dose-escalation trial, Part 2 is a pharmacokinetic comparison and food effect study, and Part 3 is extended trial of combination of utidelone capsule and capecitabine. The primary objectives are 1. To evaluate the safety and tolerability of utidelone capsules in patients with advanced solid tumors and to determine the Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT). 2. To evaluate the objective response rate in patients with advanced metastatic breast cancer treated with the combination of utidelone capsule and capecitabine. The secondary objectives are: 1. to evaluate the absolute bioavailability of utidelone capsules relative to utidelone injection; 2. to evaluate the pharmacokinetic profile of utidelone capsules in patients with advanced solid tumors; 3. to preliminarily evaluate the efficacy and safety of utidelone capsules in patients with advanced solid tumors; and 4. to recommend doses and dosing regimens for subsequent clinical trials. 5. To evaluate the Progression-Free Survival (PFS), safety and pharmacokinetics of utidelone capsule combined with capecitabine in the treatment of patients with advanced metastatic breast cancer.
Timeline
- Start
- 2023-06-09
- Primary completion
- 2025-10-08
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Epothilone D | Small molecule | 30 mg/m2 | Oral |
| Subject | Epothilone D | Small molecule | 50 mg/m2 | Oral |
| Subject | Epothilone D | Small molecule | 60 mg/m2 | Oral |
| Subject | Epothilone D | Small molecule | 75 mg/m2 | Oral |
| Subject | Epothilone D | Small molecule | 100 mg/m2 | Oral |
| Subject | Epothilone D | Small molecule | 120 mg/m2 | Oral |
Indications
No indication recorded.